Health-related quality of life associated with different cancer treatments in Chinese breast cancer survivors in Taiwan

Huang Tz Ou, Wei Pang Chung, Pei Fang Su, Tzu Hsuan Lin, Ji Ying Lin, Yao Chun Wen, Wei Tse Fang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We assessed the quality of life (QoL) associated with patient's characteristics and different cancer treatments among Chinese breast cancer survivors in Taiwan. A cross-sectional survey was conducted in 2017 where 193 patients with hormone receptor-positive/human epidermal growth factor receptor-2-negative metastatic breast cancer were recruited. Three QoL questionnaires were administered: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), its breast cancer supplementary measure (QLQ-BR23) and EQ-5D-5L. Multiple linear regression was performed to assess the association between QoL and cancer treatments, with adjustment for patient's characteristics. The mean age of study participants was 55.52 years. Simple linear regression showed that cancer stage and receiving chemotherapy were significantly associated with QoL scores (p < 0.05). Significant adverse effects of chemotherapy on QoL were found among early-stage cancer women (i.e., I or II), including poor cognitive and sexual functioning, and a higher symptom burden (i.e., dyspnoea, constipation, systematic therapy side effects). Multiple linear regression also revealed that receiving chemotherapy was significantly associated with poor QoL (e.g., lower functional health and higher symptom burden measured by the QLQ-BR23), compared to none chemotherapy (p < 0.05). Receiving chemotherapy was associated with poor QoL, especially among early-stage breast cancer patients.

Original languageEnglish
Article numbere13069
JournalEuropean Journal of Cancer Care
Volume28
Issue number4
DOIs
Publication statusPublished - 2019 Jul

Fingerprint

Taiwan
Survivors
Quality of Life
Breast Neoplasms
Neoplasms
Drug Therapy
Linear Models
Therapeutics
Constipation
Dyspnea
Cross-Sectional Studies
Organizations
Hormones
Health
Research

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

@article{ec76b9ce6372413e928ca42c8d75c64c,
title = "Health-related quality of life associated with different cancer treatments in Chinese breast cancer survivors in Taiwan",
abstract = "We assessed the quality of life (QoL) associated with patient's characteristics and different cancer treatments among Chinese breast cancer survivors in Taiwan. A cross-sectional survey was conducted in 2017 where 193 patients with hormone receptor-positive/human epidermal growth factor receptor-2-negative metastatic breast cancer were recruited. Three QoL questionnaires were administered: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), its breast cancer supplementary measure (QLQ-BR23) and EQ-5D-5L. Multiple linear regression was performed to assess the association between QoL and cancer treatments, with adjustment for patient's characteristics. The mean age of study participants was 55.52 years. Simple linear regression showed that cancer stage and receiving chemotherapy were significantly associated with QoL scores (p < 0.05). Significant adverse effects of chemotherapy on QoL were found among early-stage cancer women (i.e., I or II), including poor cognitive and sexual functioning, and a higher symptom burden (i.e., dyspnoea, constipation, systematic therapy side effects). Multiple linear regression also revealed that receiving chemotherapy was significantly associated with poor QoL (e.g., lower functional health and higher symptom burden measured by the QLQ-BR23), compared to none chemotherapy (p < 0.05). Receiving chemotherapy was associated with poor QoL, especially among early-stage breast cancer patients.",
author = "Ou, {Huang Tz} and Chung, {Wei Pang} and Su, {Pei Fang} and Lin, {Tzu Hsuan} and Lin, {Ji Ying} and Wen, {Yao Chun} and Fang, {Wei Tse}",
year = "2019",
month = "7",
doi = "10.1111/ecc.13069",
language = "English",
volume = "28",
journal = "European Journal of Cancer Care",
issn = "0961-5423",
publisher = "Wiley-Blackwell",
number = "4",

}

Health-related quality of life associated with different cancer treatments in Chinese breast cancer survivors in Taiwan. / Ou, Huang Tz; Chung, Wei Pang; Su, Pei Fang; Lin, Tzu Hsuan; Lin, Ji Ying; Wen, Yao Chun; Fang, Wei Tse.

In: European Journal of Cancer Care, Vol. 28, No. 4, e13069, 07.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Health-related quality of life associated with different cancer treatments in Chinese breast cancer survivors in Taiwan

AU - Ou, Huang Tz

AU - Chung, Wei Pang

AU - Su, Pei Fang

AU - Lin, Tzu Hsuan

AU - Lin, Ji Ying

AU - Wen, Yao Chun

AU - Fang, Wei Tse

PY - 2019/7

Y1 - 2019/7

N2 - We assessed the quality of life (QoL) associated with patient's characteristics and different cancer treatments among Chinese breast cancer survivors in Taiwan. A cross-sectional survey was conducted in 2017 where 193 patients with hormone receptor-positive/human epidermal growth factor receptor-2-negative metastatic breast cancer were recruited. Three QoL questionnaires were administered: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), its breast cancer supplementary measure (QLQ-BR23) and EQ-5D-5L. Multiple linear regression was performed to assess the association between QoL and cancer treatments, with adjustment for patient's characteristics. The mean age of study participants was 55.52 years. Simple linear regression showed that cancer stage and receiving chemotherapy were significantly associated with QoL scores (p < 0.05). Significant adverse effects of chemotherapy on QoL were found among early-stage cancer women (i.e., I or II), including poor cognitive and sexual functioning, and a higher symptom burden (i.e., dyspnoea, constipation, systematic therapy side effects). Multiple linear regression also revealed that receiving chemotherapy was significantly associated with poor QoL (e.g., lower functional health and higher symptom burden measured by the QLQ-BR23), compared to none chemotherapy (p < 0.05). Receiving chemotherapy was associated with poor QoL, especially among early-stage breast cancer patients.

AB - We assessed the quality of life (QoL) associated with patient's characteristics and different cancer treatments among Chinese breast cancer survivors in Taiwan. A cross-sectional survey was conducted in 2017 where 193 patients with hormone receptor-positive/human epidermal growth factor receptor-2-negative metastatic breast cancer were recruited. Three QoL questionnaires were administered: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), its breast cancer supplementary measure (QLQ-BR23) and EQ-5D-5L. Multiple linear regression was performed to assess the association between QoL and cancer treatments, with adjustment for patient's characteristics. The mean age of study participants was 55.52 years. Simple linear regression showed that cancer stage and receiving chemotherapy were significantly associated with QoL scores (p < 0.05). Significant adverse effects of chemotherapy on QoL were found among early-stage cancer women (i.e., I or II), including poor cognitive and sexual functioning, and a higher symptom burden (i.e., dyspnoea, constipation, systematic therapy side effects). Multiple linear regression also revealed that receiving chemotherapy was significantly associated with poor QoL (e.g., lower functional health and higher symptom burden measured by the QLQ-BR23), compared to none chemotherapy (p < 0.05). Receiving chemotherapy was associated with poor QoL, especially among early-stage breast cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=85065490628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065490628&partnerID=8YFLogxK

U2 - 10.1111/ecc.13069

DO - 10.1111/ecc.13069

M3 - Article

C2 - 31066140

AN - SCOPUS:85065490628

VL - 28

JO - European Journal of Cancer Care

JF - European Journal of Cancer Care

SN - 0961-5423

IS - 4

M1 - e13069

ER -